Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 16/20 | 0.80 |
| ▸ | PIK3CA | P42336 | 6/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.80 |
| ▸ | PIK3R1 | P27986 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453969 | 1.00 | PIK3CB (0.80) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL374947 | 0.90 | PIK3CB (1.00) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3565664 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3573707 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3565668 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL2954784 | 0.90 | PIK3CB (0.81) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3563024 | 0.87 | PIK3CA (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3570676 | 0.87 | PIK3CA (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3563020 | 0.87 | PIK3CA (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 | |
| SCHEMBL3570680 | 0.87 | PIK3CA (0.83) | PIK3CBPIK3CAPIK3CDPIK3CGPIK3R1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070244110-A1 | Treatment of prostate cancer, melanoma or hepatic cancer | ZENYAKU KOGYO KABUSHIKI KAISHA (JP) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244110-A1 | Treatment of prostate cancer, melanoma or hepatic cancer | KLK3, CYP11B1, CYP11B2 | PIK3CB 3425/4885PIK3CA 2494/4885PIK3CD 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.